These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 17339574)

  • 1. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 4. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in clinical trial design: stopping a trial early and the large and simple trial.
    Thom EA; Klebanoff MA
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 1):619-25. PubMed ID: 16150252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ethics of early stopping rules.
    Pater J; Goss P; Ingle J; Shelley W; Shepherd L
    J Clin Oncol; 2005 Apr; 23(12):2862-3; author reply 2863-4. PubMed ID: 15838002
    [No Abstract]   [Full Text] [Related]  

  • 10. The ethics of early stopping rules: who is protecting whom?
    Cannistra SA
    J Clin Oncol; 2004 May; 22(9):1542-5. PubMed ID: 15117977
    [No Abstract]   [Full Text] [Related]  

  • 11. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring clinical trials. Several points are contentious.
    Parry D
    BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
    [No Abstract]   [Full Text] [Related]  

  • 15. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 17. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 18. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 19. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerations.
    Ball G; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S8-10. PubMed ID: 21664988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.